Brought to you by 
Panacos, National Cancer Institute in HIV drug deal
Apr 2001
Executive Summary
Panacos Pharmaceuticals (antiviral drugs and vaccines) and the National Cancer Institute will collaborate to discover potential drugs that prevent HIV infection by inhibiting the virus from entering human cells.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Panacos, National Cancer Institute in HIV drug deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice